In December, 2006, the Food and Drug Administration (FDA) issued an advisory to physicians about Gadolinium, an injectable contrast agent used during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) procedures.
According to the FDA, patients who have chronic kidney problems may be at risk for developing Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD). There is no known cure for these life-threatening illnesses.
